Senkyunolide ASenkyunolide A
MedChemExpress (MCE)
HY-N0743
63038-10-8
99.32%
-80°C, protect from light, stored under nitrogen
Shipping with dry ice.
Senkyunolide A is a phthalein compound. Senkyunolide A inhibits the proliferation of tumor cells and has anticancer activity. Senkyunolide A inhibits the progression of osteoarthritis through the NLRP3 signaling pathway. Senkyunolide A protects nerve cells from Corticosterone (HY-B1618) -induced apoptosis by regulating protein phosphatase 2A and α-synuclein signaling pathways. Senkyunolide A inhibits the expression of CD137, a diagnostic biomarker for atherosclerosis.
Senkyunolide A (0-2.5 μg/mL
24 h) inhibits the proliferation of HT-29 and CCD-18Co cells with IC50 of 10.4 μM and 20.95 μM, respectively [1]. Senkyunolide A (100 μM
6 h) inhibits the high expression of CD137 in TNF-α treated MAECs cells[2]. Senkyunolide A (0.125-0.5 μg/mL
24-72 h) improves cell viability, decreases apoptosis, LDH release, α-syn expression and PP2P phosphorylation in PC12 cells treated with corticosterone (HY-B1618)[3]. Senkyunolide A (20-80 μg/mL
48 h) promotes cell proliferation and inhibits cell apoptosis in IL-1β-treated chondrocytes, and inhibits cell inflammation by blocking the NLRP3 signaling pathway[4].
Senkyunolide A (20-40 mg/kg
Intraperitoneal injection
1 week) shows improvement in the mouse model of osteoarthritis[4]. Pharmacokinetic Analysis in Rats[5] Route Dose (mg/kg) Tmax (h) Cmax (mg/L) t1/2 (h) AUC0→∞ (mg/h per liter) Vd/F (L/kg) CL/F (L/h per kilogram) F (%) i.v. 20 (pure) / 19.67 0.65 2.81 6.74 7.20 / i.v. 7.65 (ext)* / 4.86 0.69 0.95 7.12 9.17 / i.p. 50 0.04 17.60 0.67 5.29 9.98 10.92 75.3 i.p. 100 0.04 31.01 0.99 10.65 13.78 9.72 75.8 p.o. 100 0.21 1.66 0.52 1.11 68.97 94.81 7.9 *The herbal extract containing 7.65% of senkyunolide A was given at a dose of 100 mg/kg.
Caspase-1 NLRP3
Dose Route Indicator value Rat 20.000mg/kg i.v. T1/2 0.65hr Rat 20.000mg/kg i.v. Cmax 19.67mg/L Rat 20.000mg/kg i.v. AUC0-∞ 2.81mg·h/L Rat 20.000mg/kg i.v. Vd 6.74L/kg Rat 20.000mg/kg i.v. CL 7.20L/h/kg Rat 5.800mg/kg i.v. T1/2 0.69hr Rat 5.800mg/kg i.v. AUC0-∞ 0.95mg/h/L Rat 5.800mg/kg i.v. Vd/F 7.12L/kg Rat 5.800mg/kg i.v. CL/F 9.17L/h/kg Rat 5.800mg/kg i.v. Cmax 4.86mg/L Rat 50.000mg/kg i.p. Tmax 0.04hr Rat 50.000mg/kg i.p. Cmax 17.6mg/L Rat 50.000mg/kg i.p. T1/2 0.67hr Rat 50.000mg/kg i.p. AUC0-∞ 5.29mg/h/L Rat 50.000mg/kg i.p. Vd/F 9.98L/kg Rat 50.000mg/kg i.p. CL/F 10.92L/h/kg Rat 50.000mg/kg i.p. F 75.3% Rat 100.000mg/kg i.p. Rat 100.000mg/kg p.o.
| | | |
| | | | | |
[1]. Kan WL, et al. Study of the anti-proliferative effects and synergy of phthalides from Angelica sinensis on colon cancer cells. J Ethnopharmacol. 2008 Oct 30
120(1):36-43. [Content Brief]
[2]. Lei W, et al. Phthalides, senkyunolide A and ligustilide, show immunomodulatory effect in improving atherosclerosis, through inhibiting AP-1 and NF-κB expression. Biomed Pharmacother. 2019 Sep
117:109074. [Content Brief]
[3]. Gong S, et al. Senkyunolide A protects neural cells against corticosterone-induced apoptosis by modulating protein phosphatase 2A and α-synuclein signaling. Drug Des Devel Ther. 2018 Jun 25
12:1865-1879. [Content Brief]
[4]. Shao M, et al. Senkyunolide A inhibits the progression of osteoarthritis by inhibiting the NLRP3 signalling pathway. Pharm Biol. 2022 Dec
60(1):535-542. [Content Brief]
[5]. Yan R,et al. Low oral bioavailability and pharmacokinetics of senkyunolide a, a major bioactive component in Rhizoma Chuanxiong, in the rat. Ther Drug Monit. 2007 Feb
29(1):49-56. [Content Brief]